More than six million Australians suffer from chronic liver diseases, costing the nation more than $50 billion a year in health care costs and lost productivity

Sydney Health Partners’ Liver collaborative network is researching the scale-up of novel, evidence-based, interventions and their application in community and marginalised settings.

Focusing on the elimination of hepatitis C using Direct Acting Antivirals, the collaboration is enhancing sector capability, reducing clinical variation, developing platforms for data integration, increasing consumer engagement and closing the loop between health practice and research.

Network Leads

  • Professor Jacob George

    Chair of Hepatic Medicine, Sydney Medical School – University of Sydney

    Director, Storr Liver Centre - The Westmead Institute for Medical Research
    Head, Department of Gastroenterology & Hepatology - Western Sydney Local Health District

    Visit Profile of Professor Jacob George

Community Outreach to Micro-eliminate HCV

An innovative project is testing ways to micro-eliminate hepatitis C in marginalised groups as part of an aspirational goal to rid Australia of the disease.

Injecting substance users, mentally ill and homeless people, and others with hepatitis C are the targets of a community outreach program which seeks to overcome the social and practical barriers to the testing, diagnosis and prescribing of drugs to treat the disease.

Get Involved

The best way to get involved with Sydney Health Partners Liver collaborative is to contact the network lead directly.